6 episodes

Between 50 and 60 percent of patients diagnosed with colorectal cancer will develop metastases during the course of their disease, spreading to the lungs, liver, or other secondary location.
To help physicians tackle this very real threat facing their patients, Conversations on Colorectal Cancer focuses on the current guidelines and therapeutic landscape for metastatic colorectal cancer (mCRC).
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
 
 Sponsored by

Conversations on Colorectal Cancer ReachMD

    • Science

Between 50 and 60 percent of patients diagnosed with colorectal cancer will develop metastases during the course of their disease, spreading to the lungs, liver, or other secondary location.
To help physicians tackle this very real threat facing their patients, Conversations on Colorectal Cancer focuses on the current guidelines and therapeutic landscape for metastatic colorectal cancer (mCRC).
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
 
 Sponsored by

    Characteristic Clinical Presentations of Tumor Sidedness: Diagnostic & Prognostic Impacts

    Characteristic Clinical Presentations of Tumor Sidedness: Diagnostic & Prognostic Impacts

    Guest: Putao Cen, MD


    Tune in to hear Dr. Putao Cen, Associate Professor of Medical Oncology at the University of Texas Health Science Center McGovern Medical School, discussing the clinical presentations of tumor sidedness in colorectal cancer patients and how it affects diagnosis, prognosis, and treatment.

    Comparing Anti-EGFR in Left vs. Right-Sided Colorectal Cancer Tumors: Survival Trends from the Latest Clinical Trials

    Comparing Anti-EGFR in Left vs. Right-Sided Colorectal Cancer Tumors: Survival Trends from the Latest Clinical Trials

    Guest: Putao Cen, MD


    Here to give us a breakdown of what the latest clinical trials are saying about anti-EGFR therapies in left versus right-sided colorectal cancer tumors is Dr. Putao Cen, Associate Professor of Medical Oncology at the University of Texas Health Science Center McGovern Medical School.

    An Oncologist’s Keys to Managing Adverse Events in mCRC Care

    An Oncologist’s Keys to Managing Adverse Events in mCRC Care

    Guest: Putao Cen, MD


    When a patient with metastatic colorectal cancer experiences adverse events like complete obstruction and tumor perforations, it can further complicate an already-difficult disease to manage. That’s why Dr. Putao Cen is here to reveal his key strategies in managing these and other adverse events in metastatic colorectal cancer.

    Addressing Gaps in Biomarker Testing for mCRC at Diagnosis

    Addressing Gaps in Biomarker Testing for mCRC at Diagnosis

    Host: John J. Russell, MD

    Guest: Axel Grothey, MD


    Since biomarker testing can aid in the creation of individualized treatment plans, Dr. Axel Grothey is here to provide his perspective on the current state of biomarker testing for colorectal cancer and how we can increase biomarker testing practices at the time of diagnosis.

    Tumor Sidedness in mCRC: Translating the Latest Research Findings into Practice

    Tumor Sidedness in mCRC: Translating the Latest Research Findings into Practice

    Host: John J. Russell, MD

    Guest: Axel Grothey, MD


    In recent years, researchers have been investigating the role of tumor sidedness in metastatic colorectal cancer, and here to walk us through the latest findings and their application to colorectal cancer care is Dr. Axel Grothey.

    mCRC ‘State of the Union’: Current & Emerging Research Avenues to Know

    mCRC ‘State of the Union’: Current & Emerging Research Avenues to Know

    Host: John J. Russell, MD

    Guest: Axel Grothey, MD


    Since colorectal cancer continues to be one of the most common—and lethal—cancers, it should come as no surprise that much research has focused on improving the way we prevent, detect, and treat it, and joining Dr. John Russell to talk about the current and emerging research avenues in colorectal cancer is Dr. Axel Grothey.

Top Podcasts In Science